ALSO NOTED: Zingo data lifts Anesiva stock; Two chemo drugs win approvals; BrainStorm plans trials; and much more...

> Shares of Anesiva jumped after the company announced positive top-line data from a late-stage study of Zingo, its drug candidate for reducing venous procedural pain. Report

> Bristol-Myers Squibb has won the FDA's approval for the chemo drug Ixempra for breast cancer. Report

> The FDA has approved Abraxis Pharmaceutical's chemotherapy drug Epirubicin hydrochloride injection in four dosage forms. Report

> Israel's BrainStorm Cell Therapeutics says it's likely to do clinical trials of its adult stem cell therapies in New York City. Report

> Sorry, Amgen and Johnson & Johnson. So says the FDA, which is backing up Medicare's new limits on using the companies' anemia drugs Aranesp, Epogen, and Procrit. Report

> You can't accuse pharma companies of failing to think ahead. They begin to forge links with future doctors before they even start med school. Report

And Finally... In what is likely to provide a big push for antibiotic developers, a new study by the CDC shows that almost 19,000 Americans were killed by the MRSA superbug last year, making it more lethal than AIDS. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.